Reducing Disparities in Living Donor Transplant Among African Americans

Status Completed

Clinical Trial Summary

For most of the patients in the United States with end stage renal disease (ESRD), kidney transplantation represents the optimal treatment, and living donor kidney transplantation (LDKT) is preferable. Nevertheless, there are pervasive racial disparities in access to LDKT. The main outcome of this study is change in the proportion of study participants who have at least one living donor inquiry by friends/family over study period.The long-term objective is to understand the combined effect of a systems-level intervention (Transplant Referral EXchange or T-REX) and a culturally-sensitive individual-level educational intervention (web-based Living ACTS: About Choices in Transplantation and Sharing) on racial disparities in access to LDKT.

Clinical Trial Description

For most of the patients in the United States with end stage renal disease (ESRD), kidney transplantation represents the optimal treatment. Moreover, living donor kidney transplantation (LDKT) offers numerous advantages such as better kidney quality, increased short- and long-term graft survival, lower rates of acute rejection, and reduced health care cost. Nevertheless, there are pervasive racial disparities in access to LDKT, with white ESRD patients four times more likely to receive a LDKT than African American ESRD patients. The main outcome of this study is change in the proportion of study participants who have at least one living donor inquiry by friends/family over 12 months from baseline.The long-term objective is to understand the combined effect of a systems-level intervention that enhances communication between dialysis facility and transplant center clinicians (Transplant Referral EXchange or T-REX) and a culturally-sensitive individual-level educational intervention (web-based Living ACTS: About Choices in Transplantation and Sharing) on racial disparities in access to LDKT. ;

Study Design

Related Conditions & MeSH terms

Kidney Transplant

Clinical Trial Details

NCT number	NCT03819686
Study type	Interventional
Source	Emory University
Contact
Status	Completed
Phase	N/A
Start date	February 4, 2019
Completion date	January 26, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04087720` - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant	Phase 4
Completed	`NCT03749356` - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients	Phase 4
Withdrawn	`NCT05811468` - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed	`NCT03527238` - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine	Phase 2
Completed	`NCT00498576` - Melatonin and Adiponectin in Hypertensive Kidney Transplant	N/A
Completed	`NCT00642655` - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation	Phase 1/Phase 2
Completed	`NCT00374400` - The Paired Donation Consortium Paired Donation Program	N/A
Completed	`NCT01710033` - A Study Of CP-690,550 In Stable Kidney Transplant Patients	Phase 1
Completed	`NCT00205257` - Prediction of Acute Rejection in Renal Transplant	Phase 1
Completed	`NCT02711826` - Treg Therapy in Subclinical Inflammation in Kidney Transplantation	Phase 1/Phase 2
Withdrawn	`NCT03978494` - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.	Phase 1
Completed	`NCT03837522` - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT05029310` - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients	Phase 4
Completed	`NCT03644485` - Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT02409901` - Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients	N/A
Completed	`NCT01047410` - ACtive Care After Transplantation, the ACT Study	N/A
Completed	`NCT00940940` - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation	Phase 4
Completed	`NCT00270712` - A Study of Factors That Affect Long-Term Kidney Transplant Function
Completed	`NCT00217126` - The Study of Long-term Deterioration of Kidney Transplants.	Phase 4